oral, reversible, allosteric USP1 inhibitor Ph. I/II in BRCA1/2 mutant or HRD+ solid tumors, terminated from known USP1 inhibitor ACS Spring 2024 Meeting First Time Disclosure Tango Therapeutics, Boston, MA